IBB - 1 Cancer Stock to Buy and Hold for the Next Decade
While the market is hitting all-time highs, shares of the Nasdaq Biotechnology ETF (NASDAQ: IBB) are trading essentially flat year-to-date, down just over 15% from their peak. Down 11% since the beginning of the year, but up just less than fivefold over the past five years , Blueprint Medicines (NASDAQ: BPMC) has two products on the market and a clear path to continue to achieve big gains for investors in the future.
Image source: Getty Images.
Blueprint Medicines is the first and only company to have two internally discovered and developed medicines that received U.S. Food and Drug Administration (FDA) approval within a decade of founding. Not bad for a company with a market cap of only $5.4 billion. And now, it has plenty of cash and a few more potentially blockbuster ideas up its sleeve.
For further details see:
1 Cancer Stock to Buy and Hold for the Next Decade